Journal of Clinical Psychopharmacology

Secondary Logo

Journal Logo

January/February 2023 - Volume 43 - Issue 1

  • Anthony J. Rothschild, MD
  • 0271-0749
  • 1533-712X
  • 6 issues / year
  • Psychiatry 101/155; Pharmacy and Pharmacology 170/279
  • 3.118
A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia

This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology. After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at https://www.cmesurvey.site/TAAR1.
Published September/October 2022

​​​​​Photo -AJ Rothschild, MD in front of medical school.jpg​Welcome to the January/February 2023 issue of the Journal of Clinical Psychopharmacology (JCP). There are many thought-provoking and informative papers in this issue. I would like to highlight a few of them. On pages 1-2, Dr. Richard Shader, Founding Editor-in-Chief, Emeritus of JCP, has written a Guest Editorial titled, “Statistical Versus Clinical Significance: A Question About Caplyta (Lumateperone)".  In the Editorial, Dr. Shader contrasts the differences in the pictures painted by direct-to-consumer advertising on television with the data from a single published report of lumateperone for the treatment of episodes of depression in bipolar disorder.

The approval of medications for the treatment of psychiatric illness varies from country to country. In a Commentary on pages 3-5, Drs. Rishab Gupta and Swarndeep Singh critique the Indian government's decision to approve endoxifen for the treatment of acute mania in adults. 

The commentary has an accompanying podcast.​

On pages 6-11, Dr. Rakesh Kumar and colleagues, in a paper titled, “Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy," used a 2-year mirror-image study design to investigate changes in clinical characteristics, pharmacotherapeutic treatments for medical/psychiatric disorders, and outcomes among patients with bipolar disorder and chronic kidney disease on long-term lithium therapy.  

There is an accompanying podcast​ with Dr. Kumar and senior author Dr. Balwinder Singh.

Finally, on pages 12-19, Dr. Kim Dao and colleagues, in a paper titled, “Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy:  A Comparative ENTIS Cohort Study," present data from a multicenter, observational prospective cohort study which compared pregnancy outcomes in women exposed to trazodone in early pregnancy against those in a reference group of women exposed to a selective serotonin reuptake inhibitors.

And as you will see, there are many other interesting Original Contributions, Brief Reports, and Letters to the Editor in the January/February 2023 issue!​

Anthony J. Rothschild, MD

Editor-in-Chief

Current Issue Highlights




Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy

Kumar, Rakesh; Joseph, Boney; Pazdernik, Vanessa M.; More

Journal of Clinical Psychopharmacology. 43(1):6-11, January/February 2023.





Duration: 5:25

In a commentary published in the Journal of Clinical Psychopharmacology, Dr. Rishab Gupta (Brigham and Women's Hospital/Harvard Medical School) and Dr. Swarndeep Singh (Government Medical College and Hospital, Chandigarh, India) cast a critical eye on India’s regulatory approval for the use of endoxifen for the treatment of manic episodes in patients with bipolar disorder type 1. In their article and in this podcast, they suggest that there are important deficiencies in the research that was used to support the regulatory approval. No other country has approved endoxifen for treating bipolar disorder. They caution that endoxifen should be considered as an option to treat acute mania only after a careful consideration of risks/benefits with the patient and their family and after providing them with a list of alternative medications.